{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-269522","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.372473+00:00","generated_at":"2026-05-16T23:53:18.890860+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sana Q3 net loss $42.2M; shifts focus to type 1 diabetes and in vivo CAR T, suspends allogeneic CAR T","bullets":["Q3 net loss $42.2M ($0.16/share); cash $153.1M; raised $115.8M in Q3, pro forma cash $170.5M.","Prioritizing SC451 (type 1 diabetes) IND as early as 2026 and SG293 in vivo CAR T IND as early as 2027.","Suspended allogeneic CAR T programs SC291 and SC262; NEJM published positive 12-week data for UP421 showing insulin production without immunosuppression.","Non-GAAP operating cash burn $108M for 9 months; non-GAAP net loss $39M for Q3."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-269522","json":"https://secwatch.observer/filing/0001193125-25-269522.json","markdown":"https://secwatch.observer/filing/0001193125-25-269522.md","text":"https://secwatch.observer/filing/0001193125-25-269522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312525269522/0001193125-25-269522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312525269522/sana-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:53:18.890860+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}